Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper-Reference-Cited by-同舟云学术

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

Published:2022-10 Issue:10 Volume:9 Page:e786-e795
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Gagelmann Nico,Sureda Anna,Montoto Silvia,Murray John,Bolaños Natacha,Kenyon Michelle,Beksac Meral,Schönland Stefan,Hayden Patrick,Scheurer Hans,Morgan Kate,Garderet Laurent,McLornan Donal P,Ruggeri Annalisa

Funder

Gilead Sciences

Celgene

Bristol-Myers Squibb

Novartis

Janssen Pharmaceuticals

Publisher

Elsevier BV

Subject

Hematology

Reference75 articles.

1. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dimopoulos;Ann Oncol,2021

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

3. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group;Moreau;Lancet Oncol,2021

4. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma;Bruno;Haematologica,2021

5. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis;Gagelmann;Eur J Haematol,2020

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T and cellular gene therapies are too expensive;Nature Medicine;2024-09-04

2. Continued need for autologous transplantation in relapsed myeloma;The Lancet Haematology;2024-09

3. Understanding Myeloma-Related Information Needs and Communication Preferences Within Black American Communities: An Exploratory Study;Journal of Cancer Education;2024-08-16

4. Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysis;Cancer Letters;2024-07

5. Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma;Seminars in Hematology;2024-07